The company's flagship assay uses whole-genome sequencing to identify patients with high-risk multiple myeloma and determine which patients won't respond to therapies.

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical ...

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data ...

In the two decades since a young father was diagnosed with multiple myeloma, clinical trials and advances in treating his ...

The following is a summary of “Epidemiology of patients treated for multiple myeloma using a new algorithm in the French ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and ...

As the authors reported in Radiology Case Reports, the patient had no history of cancer and had no pain, weakness, numbness, or other spine-related symptoms. Lab tests confirmed she had severe anemia; ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard reveals how multiple myeloma, a form of blood cancer, begins and ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital reveals how multiple myeloma, a form of ...

Farber Cancer Institute and the Broad Institute of MIT and Harvard reveals how multiple myeloma, a form of blood cancer, begins and progresses from precancerous to malignant states by tracing DNA ...